This is an international site for Glivec® (imatinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
Survey
Help us improve Glivec.com. Please take our short survey.
May 7, 2009 Glivec® approved in EU as first post-surgery therapy to reduce risk of cancer returning in patients with aggressive gastrointestinal tumors
U.S. Residents
